Nodality Launches PathPro™ T Cell Receptor (TCR) and B Cell Receptor (BCR) Panels for Assessing Drug Impact on Functional Signaling in Primary Human Cells

Nodality, Inc. announced today the availability of its new PathPro™ T Cell Receptor (TCR) and B Cell Receptor (BCR) panels. These panels provide unique insights into disease and the impact of a compound or drug on BCR or TCR signaling in primary human cells. Each is designed to characterize cell signaling pathways at the single cell level for broad application in multiple therapeutic areas including autoimmune disease and cancer immunotherapy. Earlier this year, Nodality introduced its first PathPro products, which leverage the unique capabilities of Nodality’s proprietary multiparametric flow cytometry platform to study the functional activity of customer therapeutics. In addition to the PathPro TCR and BCR panels, Nodality has launched PathPro JAK-STAT, PathPro TLR, PathPro AML, and PathPro CLL panels, all focused on solving drug development challenges.

“We are excited to further expand our PathPro™ product offerings, providing an increasingly comprehensive suite of products that can serve diverse needs in drug development,” said Laura Brege, CEO and President of Nodality, Inc. “Our TCR and BCR panels provide a robust way to analyze single cell signaling in a human translational model, targeting a spectrum of key immune signaling pathways critical to understanding drug function.”

Nodality’s PathPro products are based on the Company’s broad knowledge and experience in diverse signaling pathways and in interrogating signaling at the single cell level in numerous cell types including rare cell subtypes. For each PathPro product, customers are able to select modulators, pathways, cell types and donor sample types to be interrogated in targeted, small-scale studies. The results provide critical insights into the functional impact of drugs and drug candidates in disease sub-groups, while also identifying differential in vitro activities, pathway-specific profiles and/or disease profiles, and informing on mechanism of action (MOA), efficacy and comparison of compound activities.

• PathPro™ T Cell Receptor (TCR) panel
  
  Nodality's PathPro T Cell Receptor (TCR) panel enables simultaneous quantitative measurement of signaling and compound activity in many cell types in the context of TCR signaling. A wide range of drugs, both approved and in development, specifically target T cells in order to manipulate the immune system to fight cancer, resolve infections and improve the health of patients suffering from autoimmune diseases. Nodality’s quantitative PathPro TCR assay measures the activation of downstream effector molecules resulting from TCR engagement, both proximal to the TCR (e.g. p-ZAP-70, p-CD247) and more distal in the pathway (e.g. p-ERK, IkBa). This provides an opportunity to interrogate specific and differential effects of compounds or antibodies on the capacity of T cell subset activation from healthy donors and patients. For more information on the PathPro T Cell Receptor (TCR) panel, please visit http://www.nodality.com/products-standard-tcr.html.
• PathPro™ B Cell Receptor (BCR) panel
  
  Nodality’s PathPro BCR panel leverages the unique capabilities of SCNP by enabling simultaneous quantitative measurement of signaling and compound activity in many cell types in the context of BCR signaling. Nodality’s quantitative PathPro BCR assay measures the activation of downstream effector molecules resulting from BCR engagement, both proximal to the BCR (e.g. p-ZAP70, p-PLCg2) and more distal in the signaling pathway (e.g. p-ERK, IkBa), providing an opportunity to interrogate specific and differential effects of compounds or antibodies on the capacity of B cell subset activation from healthy donors and patients. For more information on the PathPro B Cell Receptor (BCR) panel, please visit http://www.nodality.com/products-standard-bcr.html.

About Single Cell Network Profiling

Nodality’s proprietary Single Cell Network Profiling (SCNP) technology, a multiparametric flow cytometry-based platform, provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology by characterizing cell signaling networks in millions of cells at the single cell level. It creates competitive advantages in addressing many of the most pressing challenges in drug discovery and development. SCNP technology, coupled with Nodality’s proprietary data analysis and visualization tools, uniquely reveals complex functional biology to inform more effective drug development decisions.

About Nodality

Nodality is a life science company whose technology platform, SCNP, bridges the gap left by traditional R&D approaches. Nodality provides clinically actionable solutions throughout the full discovery and development process, including disease profiling, drug profiling, clinical development, and life cycle management. Nodality’s team has expertise in identifying solutions across a broad therapeutic landscape, with a focus on immunology and oncology, including immuno-oncology. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.

For more information on Nodality, please visit www.nodality.com.